Pharmacokinetic Considerations for Organ Dysfunction Clinical Trials in Early Drug Development

A Azaro, ME Demirhan, J Lim, J Rodon - Phase I Oncology Drug …, 2020 - Springer
It is not infrequent that patients with different cancers are affected by bodily organ
dysfunction. Factors such as comorbidities, prior anticancer therapies and tumor-related …
相关文章

Pharmacokinetic Considerations for Organ Dysfunction Clinical Trials in Early Drug Development

A Azaro, ME Demirhan, J Lim, J Rodon - Phase I Oncology Drug …, 2020 - hero.epa.gov
It is not infrequent that patients with different cancers are affected by bodily organ
dysfunction. Factors such as comorbidities, prior anticancer therapies and tumor-related …

Pharmacokinetic Considerations for Organ Dysfunction Clinical Trials in Early Drug Development

A Azaro, ME Demirhan, J Lim… - Phase I Oncology Drug …, 2020 - books.google.com
It is not infrequent that patients with different cancers are affected by bodily organ
dysfunction. Factors such as comorbidities, prior anticancer therapies and tumor-related …

Pharmacokinetic Considerations for Organ Dysfunction Clinical Trials in Early Drug Development

A Azaro, ME Demirhan, J Lim, J Rodon - Phase I Oncology Drug Development - Springer
It is not infrequent that patients with different cancers are affected by bodily organ
dysfunction. Factors such as comorbidities, prior anticancer therapies and tumor-related …

Pharmacokinetic considerations for organ dysfunction clinical trials in early drug development

A Azaro, ME Demirhan, J Lim… - Phase I Oncology …, 2020 - mdanderson.elsevierpure.com
It is not infrequent that patients with different cancers are affected by bodily organ
dysfunction. Factors such as comorbidities, prior anticancer therapies and tumor-related …